International Task Force for Prevention of
Coronary Heart Disease
CORONARY HEART DISEASE: REDUCING THE RISK
After the patient has been assessed as detailed in
sections 2.1 (Personal and family history)
to
2.3 (Biochemical and laboratory risk factors),
his/her risk of developing CHD can be estimated. This assessment is of central
importance, since it determines the goals of therapy and thus the intensity
of treatment. As in all areas of medical practice, the risk review implies
the clinical judgement of the individual patient and his/her unique circumstances.
Today the doctor can draw on a body of evidence from epidemiological studies
and from prospective clinical trials to inform clinical assessment and to
guide therapeutic decision-making. Both approaches may be used in complementary
fashion to assess the individual risk and to decide on the correct modality
and intensity of treatment.
The goal of risk assessment is to determine an appropriate type and
intensity of treatment. In the case of lipid risk fac-tors, this
implies deciding how intensive a diet is needed, whether a drug is
required and if so at what dosage, and what target levels to aim for.
This may be achieved by judging whether the patient is at average risk
or whether she/he falls into one of the three grades of increased risk
indicated below
(2.5.1.1 to
2.5.1.3). This may be undertaken using
clinical judgment, i.e. by recording the risk factors present and
noting their number and severity or by employing quantitative risk
assessment, using risk algorithms from the Framingham or PROCAM (Figure 2)
studies.
2.5.1 Grades of increased risk
2.5.1.1 Small increase in risk
2.5.1.2 Moderate increase in risk
The risk calculator programme (available on the Task Force homepage at: http://www.chd-taskforce.com or http://chd-taskforce.de) may be used to quantify global risk based on the nine independent risk determinants defined in the Münster Heart Study (PROCAM) 15. . This facilitates clinical decision-making as is shown in the following illustrative cases. Patients 1 and 3 are rare in clinical practice but illustrate the concept of global risk; most patients falls between these two extremes.
Example 1. Solitary elevated LDL-cholesterol (180 mg/dL (4.7 mmol/L))
A 45-year-old man with systolic blood pressure 130 mmHg, HDL-cholesterol
49 mg/dL, triglyceride 90 mg/dL, LDL-cholesterol 180 mg/dL, non-smoker,
non-diabetic, no family history of myocardial infarction, no history of
angina pectoris: the risk of an acute event (fatal or non-fatal MI,
sudden cardiac death) in this man, despite a high LDL-cholesterol level,
is only 14.1 per 1000 in 8 years, or 0.18% per year, i.e. he falls into
the second quintile of risk, i.e. "small increase in risk".
Example2. Multiple risk factors, elevated LDL-cholesterol (180 mg/dL (4.7 mmol/L))<(i>
A 45-year-old man with systolic blood pressure 180 mmHg, HDL-cholesterol
30 mg/dL, triglyceride 250 mg/dL, LDL-cholesterol 180 mg/dL, smoker,
non-diabetic, positive family history of MI, positive history of angina
pectoris: the risk of an acute event in this man is 625 per 1000 in 8
years or 8% per year, i.e. he falls into highest quintile of risk.
Example 3. Muliple risk factors, normal LDL-cholesterol (100 mg/dL (2.6 mmol/L))
A 45-year-old man with systolic blood pressure 180 mmHg, HDL-cholesterol
30 mg/dL, triglyceride 250 mg/dL, LDL-cholesterol 100 mg/dL, smoker,
non-diabetic, family history of MI, positive history of angina pectoris:
the risk of an acute event in this man, despite the normal LDL-cholesterol,
is 267 per 1000 in 8 years or 3% per year, i.e. he too falls into the
highest quintile of risk.